 "Dr Reddy's completes purchase of Fondaparinux")
Dr Reddy's Laboratories today said it has completed purchase of anti-coagulant drug Fondaparinux sodium from its Australian partner Alchemia Limited announced in September.
The company has paid $17.5 million to Alchemia towards purchase of world-wide exclusive intellectual property rights for the drug.
Shareholders of Australian drug discovery and development company have approved sale of Fondaparinux at company's annual general meeting held on November 10, post which Dr Reddy's executed a purchase and sale agreement.
The agreement is effective July, 2015, according to a press release. Fondaparinux is a generic version of anticoagulant drug Arixtra.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app